Trevena, Inc. announced the completion of its previously announced leadership transition with Carrie L. Bourdow, formerly the Company's Executive Vice President and Chief Operating Officer, assuming the role of President and Chief Executive Officer. In connection with this transition, Ms. Bourdow also was appointed to the Company's Board of Directors. Maxine Gowen, Ph.D., the Company's founding President and CEO, has retired, and remains a member of the Board of Directors.

Trevena also announced the appointment of Scott Braunstein, M.D., to its Board of Directors. In conjunction with Dr. Braunstein's appointment, Adam M. Koppel, M.D., Ph.D., has stepped down from the Board of Directors to focus on his responsibilities as a Managing Director at Bain Capital. Dr. Koppel has served on the Board of Directors since 2014 and has played an integral role in shaping the Company's direction, including today's appointments of Ms. Bourdow and Dr. Braunstein.

Dr. Braunstein currently is an Operating Partner at Aisling Capital, where he has served since 2015. Ms. Bourdow has served in various senior positions at Trevena since May 2015. She joined the Company as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018.

Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co., Inc. in January 2015.